Potassium-competitive acid blockers (PCABs) such as vonoprazan represent a novel class of acid suppressants that show tremendous promise to enhance care of acid peptic disorders.

Potassium‐competitive acid blocker (PCAB) is a recent alternative to proton pump inhibitor (PPI) for potent acid suppression. The current systematic review and meta‐analysis aimed to compare the efficacy and safety of PCAB versus PPI in treating gastric acid‐related diseases.

Potassium-competitive acid blockers (P-CABs) are novel drugs that bind reversibly to K + ions and block the H +, K + ATPase enzyme, thus preventing acid production. P-CABs have a fast onset of action and have dose-dependent effects on acid production.

PCAB is a new class of acid suppressant agents that inhibit gastric H + K + ATPase with a faster onset of action than PPI [42]. It is non-inferior to PPI to heal esophagitis. PCAB may heal esophagitis and reduce symptoms in patients who failed to respond to PPI therapy.

Oct 12, 2022 · The first PCAB approved by the US Food and Drug Administration, vonoprazan, reversibly binds to the α-subunit of H +, K +-ATPase to compete with potassium binding. Vonoprazan is acid stable, eliminating the need for enteric coating and allowing for …

Apr 23, 2024 · Potassium-competitive acid blockers (P-CABs), such as vonoprazan and tegoprazan, are a new class of antisecretory medications that may potentially provide more potent acid inhibition than PPIs, and randomized trial data evaluating the efficacy of P-CABs in a variety of upper GI conditions are increasingly available. 5,69 Given accumulating data ...

May 1, 2024 · Potassium competitive acid blockers (P-CAB) are promising alternatives to proton pump inhibitors (PPI). We aimed to compare the efficacy and safety of P-CAB and PPI in healing grade C/D esophagitis to aid clinical decision-making.

A potassium-competitive acid blocker (PCAB), a novel class of antisecretory medication that offers more effective suppression of stomach acid than PPIs, is a possible substitute treatment . PCABs inhibit gastric acid secretion by competitively binding to the potassium-binding site of the H+/K+ ATPase enzyme, blocking the final step of acid ...

Oct 25, 2018 · Dexlansoprazole-modified release (MR), a PPI with an extended plasma residence time when given once daily, was as effective as a PPI twice daily for controlling symptoms in patients with difficult-to-control reflux disease [1, 17].

Oct 2, 2022 · Background and aim: Potassium-competitive acid blocker (PCAB) is a recent alternative to proton pump inhibitor (PPI) for potent acid suppression. The current systematic review and meta-analysis aimed to compare the efficacy and safety of PCAB versus PPI in treating gastric acid-related diseases.